Table 1.

Percentage of PTH (1-84) treated patients with hypercalcemia or hypercalciuria in the PHASEII, TOP, OLES, POWER, PaTH, and PEAK studies. The level of serum and urinary calcium at which the patients were excluded from the trials, and the level at which hypercalcemia and hypercalciuria were defined are shown, when published in the studies

Trial	Excluding calcemia	Hypercalcemia defined as	Hypercalcemic patients in %		Excluding calciuria	Hypercalciuria defined as	Hypercalciuria patients in %
			PTH (1-84)	Other group			PTH (1-84)	Other group
PhaseII4	Not indicated	>2.64 mmol/L or 10.6 mg/dL	4.3%
TOP18	>2.66 mmol/L or 10.7 mg/dL	>2.66 mmol/L or 10.7 mg/dL	27.8%	4.5% placebo	Ca/Creatinine ≥1.0	>9.0 mmol/24 h or 360 mg/24 h Ca/ ≥1.0	46%	23% placebo
OLES50	Same of TOP	Same of TOP	7.7% first 6 months	4.7% no PTH for 12 m
POWER22	>2.6 mmol/L or 10.7 mg/dL	Not indicated	14.4%	0%	Ca/Creatinine ≥1.5	Not indicated	43.3%	16.7%
PaTH 1° year20	>2.6 mmol/L or 10.3 mg/dL	>2.62 mmol/L or 10.5 mg/dL	12%	14% Creatinine PTH + Aln 0% Aln	Ca/Creatinine ≥0.3	>9.98 mmol/24 h or 400 mg/24 h	8%	11% PTH + Aln 0% Aln
PEAK51	Not indicated	>2.67 mmol/L or 10.7 mg/dL	5% first 12 months